Targeting PKM2 Enhances the Anti-Tumor Function of CD8+ T Cells Through Metabolic Reprogramming
International Journal of Molecular Sciences · 2026
DOI: 10.3390/ijms27177664 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Junxiu Zhang und 5 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Wannan Medical University, 22 Wenchang West Road, Higher Education Park, Wuhu 241002, China. Hauptthemen laut MEDLINE: CD8-Positive T-Lymphocytes, Melanoma, Experimental, Membrane Proteins, Carrier Proteins. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, High-level Talent Scientific Research Startup Foundation of Wannan Medical College, Anhui Provincial University Natural Science Research Project.
Abstract (Originalsprache)
The efficacy of adoptive cell transfer (ACT) therapy in solid tumors is often limited by the functional exhaustion and insufficient persistence of infused CD8+ T cells within the tumor microenvironment. Through the integrated analysis of single-cell transcriptomic data, this study identified enolase 1 (ENO1), a key rate-limiting enzyme in glycolysis, as a core gene highly correlated with the superior anti-tumor phenotype of tumor-infiltrating lymphocytes (TILs). However, in vitro functional validation demonstrated that the overexpression of Eno1 failed to substantially enhance the anti-tumor efficacy of mouse T cells, suggesting the presence of a downstream metabolic regulatory node within the glycolytic cascade that restricts the conversion of carbon flux. To overcome this limitation, we introduced the small molecule activator TEPP-46 to target a crucial downstream metabolic hub, pyruvate kinase M2 (PKM2). Transcriptome sequencing confirmed that PKM2 activation successfully induced systemic metabolic rewiring in CD8+ T cells and broadly upregulated the expression of cytotoxicity- and memory-related genes. In an in vivo B16-OVA melanoma model, OT-1 T cells subjected to In vitro TEPP-46 pretreatment exhibited significantly enhanced tumor-suppressive capabilities and effectively promoted the preferential differentiation of T cells into central memory T cells (Tcm). In summary, this study highlights the importance of targeting downstream metabolic nodes to bypass intrinsic metabolic restrictions in T cells. It demonstrates that in vitro metabolic pretreatment via PKM2 activation represents an effective translational strategy for optimizing the anti-tumor efficacy of ACT cell products.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmacy, Wannan Medical University, 22 Wenchang West Road, Higher Education Park, Wuhu 241002, China.
- Pharmacology Laboratory of Traditional Chinese Medicine, Wannan Medical University, 22 Wenchang West Road, Higher Education Park, Wuhu 241002, China.
ORCID-Profile: Peiwei Yang
Förderung
- National Natural Science Foundation of China
- High-level Talent Scientific Research Startup Foundation of Wannan Medical College
- Anhui Provincial University Natural Science Research Project
- Wuhu Science and Technology Plan Project
- National Natural Science Foundation
Zitieren
APA
Zhang, J., Wu, S., Yin, Q., Liu, Y., Zheng, S., & Yang, P. (2026). Targeting PKM2 Enhances the Anti-Tumor Function of CD8+ T Cells Through Metabolic Reprogramming. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27177664
Vancouver
Zhang J, Wu S, Yin Q, Liu Y, Zheng S, Yang P. Targeting PKM2 Enhances the Anti-Tumor Function of CD8+ T Cells Through Metabolic Reprogramming. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27177664
BibTeX
@article{Zhang2026,
author = {Zhang, Junxiu and Wu, Shuyi and Yin, Qin and Liu, Yanglin and Zheng, Shuguo and Yang, Peiwei},
title = {Targeting PKM2 Enhances the Anti-Tumor Function of CD8+ T Cells Through Metabolic Reprogramming},
journal = {International Journal of Molecular Sciences},
year = {2026},
doi = {10.3390/ijms27177664}
}
EUVIMED